Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib
Posted innews OB/GYN & Women’s Health Oncology

Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib

A US cohort study of 543 ovarian cancer patients revealed 37% experienced decreased platelets during niraparib maintenance. Onset typically occurred within 1 month but resolved rapidly with dose adjustments, resulting in low discontinuation rates (16%). However, discontinuations often lacked prior dose modification, indicating management optimization opportunities.
Molecular Complexity of Endometrial Cancer: How Biomarker Patterns Vary Across Tumor Stages, Histology, and Molecular Subtypes
Posted innews OB/GYN & Women's Health Oncology

Molecular Complexity of Endometrial Cancer: How Biomarker Patterns Vary Across Tumor Stages, Histology, and Molecular Subtypes

A real-world study of 671 endometrial cancer patients reveals significant molecular heterogeneity. PTEN, ARID1A, and PIK3CA are the most prevalent biomarkers, while TP53 mutations and ERBB2 amplification cluster in advanced-stage and non-endometrioid tumors. The findings underscore the need for comprehensive molecular profiling to guide personalized treatment strategies.
Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit
Posted inCardiology Internal Medicine news

Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit

A large target‑trial emulation of US claims data found continued oral anticoagulation after ≥90 days for unprovoked VTE markedly reduced recurrent VTE and mortality, increased major bleeding, but produced an overall net clinical benefit that persisted through several years of follow‑up.